TOLREMO therapeutics AG

📍 Muttenz, Switzerland🗓 Founded 2017👥 11 employees💰 Last funded Oct 2018
Pharmaceutical Manufacturing🌐 tolremo.com
Website LinkedIn
TOLREMO therapeutics AG (“TOLREMO”) is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering real-world medicine, TOLREMO created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem. The company develops resistance-breaking add-on therapies that extend the therapeutic benefit of oncogene-targeting cancer drugs by eliminating resistance-causing persister cells (Adaptive Drug Resistance). TOLREMO’s unique drug resistance platform has the potential to catalyze a new wave of potent resistance-breaking molecules that will meaningfully extend the lives of patients suffering from cancer. To learn more visit www.tolremo.com.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in TOLREMO therapeutics AG?
TOLREMO therapeutics AG has 1 investors on record on gritt.io, including 1 early-stage backers.
When did TOLREMO therapeutics AG last raise funding?
The most recent investment in TOLREMO therapeutics AG recorded on gritt.io was in October 2018.
When was TOLREMO therapeutics AG founded?
TOLREMO therapeutics AG was founded in 2017.
What industry is TOLREMO therapeutics AG in?
TOLREMO therapeutics AG operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is TOLREMO therapeutics AG based?
TOLREMO therapeutics AG is headquartered in Muttenz, Switzerland.